Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$83.63 USD

83.63
1,031,715

-0.69 (-0.82%)

Updated Aug 9, 2024 12:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Will Moderna Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Moderna

Tirthankar Chakraborty headshot

Top Stock Trades to Beat Coronavirus Blues in April

The coronavirus pandemic has hit markets bad. But investors shouldn't shun stocks in April but should instead look for avenues to invest in areas under focus owing to rise in infected cases.

Moderna (MRNA) Gains But Lags Market: What You Should Know

Moderna (MRNA) closed the most recent trading day at $30.48, moving +1.43% from the previous trading session.

Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine

Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.

Top Ranked Momentum Stocks to Buy for March 30th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 30th

Why Is Moderna (MRNA) Up 6.8% Since Last Earnings Report?

Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences

The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences

Manaswita Ghosh Dutta headshot

3 Best U.S. Stocks Immune to Coronavirus Jitters

The pandemic may be taking a toll on markets right now but this temporary phase offers investors a window to buy equities that have a record of performing better than the broader markets.

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals

Daniel Laboe headshot

How To Play The W-Shaped Recovery

Patience is the name of the game during market downturns

Novavax Rallies as Influenza Vaccine Meets All Goals in Study

Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.

Daniel Laboe headshot

Top 5 Drug Stocks To Stop The Coronavirus Pandemic

It is only a matter of time before this virus anxiety is a thing of the past.

Coronavirus Drug Development Race to Boost These 4 Stocks

Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.

Aytu BioScience to Issue Coronavirus Rapid Test in North America

Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.

Hoth Surges on Collaboration With Voltron for COVID-19 Vaccine

Hoth (HOTH) soars following a joint venture with Voltron Therapeutics for a vaccine for COVID-19.

Axsome Expedites Completion Timeline of AD Study on AXS-05

Axsome (AXSM) speeds up the evaluation time of AXS-05 under the phase II/III ADVANCE-1 study for Alzheimer's disease agitation to ensure safety of patients amid the COVID-19 pandemic.

Moderna (MRNA) Stock Moves -0.46%: What You Should Know

In the latest trading session, Moderna (MRNA) closed at $28.14, marking a -0.46% move from the previous day.

Gilead's HCV Drug Epclusa Gets FDA Nod for Expanded Age Group

The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.

Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine

Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.

The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals

The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals

Roche to Evaluate Actemra for Severe COVID-19 Pneumonia

Roche (RHHBY) works with the FDA to evaluate the safety and efficacy of rheumatoid arthritis drug, Actemra, in severe COVID-19.

Debanjana Dey headshot

4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis

Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.

Ekta Bagri headshot

Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus?

Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.

Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

The Zacks Analyst Blog Highlights: CLX, MRNA, TDOC and ATVI

The Zacks Analyst Blog Highlights: CLX, MRNA, TDOC and ATVI